COVID-19：エジプト・ベンハ大、イベルメクチン治験：ランダム化試験（動画）：
Benha Univ: Randomized Controlled Trial Shows Ivermectin for COVID-19:
Benha大学的突破：随机对照试验显示伊维菌素可有效治疗COVID-19
エジプトのベンハ大学：
最近、「COVID-19治療と予防のための、イベルメクチンの有効性」というタイトルの臨床試験が、終了しました。
イベルメクチンの治験結果は、有望です。
Ahmed Elgazzar博士：Benha大学研究チーム
臨床試験で、「抗寄生虫薬イベルメクチンが、実際にCOVID-19患者治療に効果的な薬であること」を、さらに確認しました。
治験の結果：
イベルメクチン治験薬は、「ヒドロキシクロロキンと標準治療のみ」と比較して、死亡率の低下をもたらしました。
また、イベルメクチンの早期使用は
COVID-19感染の抑止に、もちろん効果的、
予防薬として使用すること、だけでなく、
致命的なサイトカインストームの改善に貢献します。
The Study
With accumulating evidence of
not only the efficacy of Ivermectin
but also the prominent role being played by Egyptian research centers,
this Benha University-based study sought to investigate Ivermectin from a few different important angles.
The team designed a
multicenter,
randomized,
controlled clinical trial (RCCT)
involving 600 subjects,
including 400 COVID-19 diagnosed patients and
200 health care (e.g., health professionals & workers) and
household contacts at Benha and Kafrelsheikh University hospitals.
The study commenced
on June 8 and concluded on September 15, 2020.
They evaluated Ivermectin plus the standard of care for this region, which includes azithromycin, vitamin C, Zinc, Lactoferrin and Acetylcysteine and prophylactic or therapeutic anticoagulation
Additionally and importantly, the investigational team
probed the prophylaxis benefit of health care and/or household contacts in comparison to Hydroxychloroquine plus standard treatment.
Involving 600 subjects, the study design split the patients by 400 symptomatic patients confirmed with COVID-19;
200 health care and house hold contacts distributed over 6 groups including the following –
The study team
reported that those patients receiving Ivermectin reported “substantial recovery of laboratory investigations” coupled with “significant reduction in RT-PCR conversion days.”
They report that those patients receiving Ivermectin experienced a “substantial improvement and reduction in mortality rate.”
TrialSite summarizes the results: